Get the Daily Brief
Latest Biotech News
Gene‑therapy commercial pullback — costs, uptake and regulatory friction bite
Analysts and industry observers report a marked commercial slowdown for gene therapies as pricing levels in the millions and lower-than-expected patient uptake squeeze market prospects. Firms are...
SpatialBench benchmark: agents tested on 146 realistic spatial biology tasks
SpatialBench introduced a suite of 146 verifiable problems drawn from real spatial biology workflows to evaluate AI agents on tasks ranging from QC to spatial analysis across platforms including...
Biopharma fundraising snapshot — year‑to‑date totals through Dec. 24, 2025
A year‑end compilation reports total money raised by biopharma companies (public, private and other financings) through Dec. 24, 2025, providing a consolidated view of capital flows for the...
Hanx Bio IPO tumbles 46% on HK debut despite $75M raise
Hanx Biopharmaceuticals raised HK$586 million (about US$75 million) in its Hong Kong IPO but saw its stock plunge roughly 46% on debut, signaling weak investor reception for some clinical‑stage...
Sanofi pays $2.2B for Dynavax – bolsters vaccine pipeline
Sanofi agreed to acquire Dynavax Technologies for approximately $2.2 billion in cash, consolidating a commercial hepatitis B vaccine and a clinical-stage shingles candidate under Sanofi’s vaccines...
FDA approves Yartemlea: first treatment for TA‑TMA
The U.S. Food and Drug Administration approved Omeros Corporation’s Yartemlea (narsoplimab) as the first therapy for hematopoietic stem cell transplant‑associated thrombotic microangiopathy...
Medicare to test GLP‑1 coverage – payer access inflection
CMS announced a voluntary model to test coverage pathways that would enable Medicare Part D plans and state Medicaid programs to cover GLP‑1 drugs prescribed for weight management. The pilot...
HHS proposes rollback of health‑tech rules – AI transparency pared back
HHS published a proposed rule that would roll back several Biden‑era policies, eliminate many health‑tech certification criteria and remove planned transparency requirements for healthcare AI...
Court overturns FDA LDT rule – labs win major regulatory reprieve
A federal court struck down the FDA’s final rule to regulate lab‑developed tests (LDTs), handing a significant regulatory victory to laboratories and diagnostic trade groups. The decision halted...
Engineered vesicles boost oral antibiotics... protect gut microbiome
Researchers published a Nature Communications study describing engineered vesicles that enhance oral antibiotic absorption while reducing gut dysbiosis. The vesicles act as protective carriers...
Gene therapy market cools – costs and regulation bite
Industry analysis shows commercial headwinds for gene therapy: runaway costs, limited patient uptake and regulatory challenges have damped the field’s commercial momentum. Companies report pricing...
Germline DNA‑repair defects tied to early GI cancers – screening signal
A multi‑center genetics study identified germline DNA repair deficiencies as a driver of early‑onset gastrointestinal cancers, linking inherited repair pathway defects to earlier presentation and...
FDA clears Crescom’s MediAI‑BA: AI pediatric bone‑age tool
Crescom Co. Ltd. received U.S. FDA 510(k) clearance for MediAI‑BA, an AI‑powered pediatric and adolescent bone age analysis software. The class II device evaluates hand/wrist X‑rays to estimate...
Biopharma fundraising: year‑end totals and multi‑year flows
Market trackers released year‑to‑date and historical tallies of capital raised by biopharma through Dec. 24, 2025, providing a snapshot of venture, public and other financings across the sector....
Sanofi pays $2.2B for Dynavax — MS CRL clouds pipeline
Sanofi agreed to buy Dynavax Technologies for $2.2 billion in cash, acquiring the commercial hepatitis B vaccine Heplisav‑B and a phase I/II shingles candidate. The acquisition closes a gap in...
CMS to pilot GLP‑1 coverage: Medicare edges into obesity drugs
CMS announced a voluntary model test that would enable Medicare Part D plans and some state Medicaid programs to cover GLP‑1 drugs prescribed for weight management. The model is being framed as a...
FDA clears Yartemlea — first therapy for stem‑cell transplant TA‑TMA
The U.S. FDA approved Omeros Corporation’s Yartemlea (narsoplimab) as the first treatment for hematopoietic stem cell transplant‑associated thrombotic microangiopathy (TA‑TMA), a life‑threatening...
Court tosses FDA LDT rule — 2025 regulatory climax
A federal court struck down the FDA’s final rule to regulate laboratory‑developed tests (LDTs), marking a major judicial check on agency rulemaking in 2025. The decision halted a broad effort by...
HHS proposes rule overhaul: trims AI, transparency requirements
The Department of Health and Human Services proposed regulatory changes that would roll back several Biden‑era policies, reduce health tech certification criteria and eliminate planned...
Vyriad closes $25M tranche — funds in vivo CAR‑T (VV‑169) clinic push
Vyriad closed a $25 million final tranche in its Series B, taking the round to $85 million to support first‑in‑human testing of VV‑169, an in vivo CAR‑T candidate for relapsed or refractory...